Screener
PTC Therapeutics PTCT Emflaza — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by PTC Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: PTC Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:32 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001070081-26-000012
| (in thousands) | Three Months ended March 31, 2026 / United States | Three Months ended March 31, 2026 / International | Three Months ended March 31, 2026 / Total | Three Months ended March 31, 2025 / United States | Three Months ended March 31, 2025 / International | Three Months ended March 31, 2025 / Total |
|---|---|---|---|---|---|---|
| Sephience | $112,040 | 12,511 | $124,551 | — | — | — |
| Translarna | — | 58,976 | 58,976 | — | 86,154 | 86,154 |
| Emflaza | 21,478 | — | 21,478 | 47,789 | — | 47,789 |
| Upstaza/Kebilidi | 2,998 | 6,596 | 9,594 | — | 8,659 | 8,659 |
| All other products | — | 10,974 | 10,974 | — | 10,824 | 10,824 |
| Total net product revenue | $$136,516 | $89,057 | $225,573 | $47,789 | $105,637 | 153,426 |
Item 1. Financial Statements (unaudited)
FAQ
- What is PTC Therapeutics's emflaza — revenue?
- PTC Therapeutics (PTCT) reported emflaza — revenue of $21.48M in Q1 2026.
- How has PTC Therapeutics's emflaza — revenue changed year-over-year?
- PTC Therapeutics's emflaza — revenue decreased by 55.1% year-over-year, from $47.79M to $21.48M.
- What is the long-term trend for PTC Therapeutics's emflaza — revenue?
- Over 4 years (2021 to 2025), PTC Therapeutics's emflaza — revenue has grown at a -6.0% compound annual growth rate (CAGR), from $187.2M to $146.36M.
- What does emflaza — revenue mean?
- This metric represents the net revenue generated from the sale of the Emflaza product, excluding any taxes collected from customers that are remitted to governmental authorities. It serves as a primary indicator of the product's market demand and commercial performance within the biopharmaceutical portfolio. Tracking this figure allows investors to assess the underlying top-line growth trajectory of the specific therapeutic asset independent of tax-related fluctuations.
Ask your AI about PTC Therapeutics's emflaza — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude